Reference Detail

Request Content

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

Ref Type Abstract
PMID
Authors J. Zhu Z. Song Y. Zhao J. Zhang Y. Li D. Li R. Schneider Y. Ding Z. Sun Y. Qin Z-W. Chang Z. Wang Z. Zhang P. Zhang Y. Wang J. Zhang
Title 45O First-in-human study of ABSK061: A selective fibroblast growth factor receptor (FGFR) 2/3 inhibitor for treating patients with advanced solid tumors
Journal Vol Issue Date Pages Journal Short Title
ESMO Open 9 Supplement 1 February 2024 102274 ESMO Open
URL https://www.esmoopen.com/article/S2059-7029(24)00042-5/fulltext
Abstract Text Background Aberrant activation of FGFR signaling promotes cancer cell proliferation and tumor growth. Targeting FGFR2/3 selectively may alleviate FGFR1-dependent hyperphosphatemia and could provide better efficacy. Here, we evaluated the safety and pharmacokinetics of a selective and potent FGFR2/3 inhibitor ABSK061 in advanced solid tumors in a phase 1 open-label study (NCT05244551). Methods As of November 2023, a total of 28 patients with advanced solid tumors were enrolled in the escalation part of the study. These patients were treated with ABSK061 twice daily (5mg-100mg BID) or once daily (150mg QD) in 28-day cycles. 75mg BID and 150mg QD were selected to explore the recommended doses for expansion. Results Among the 28 patients, the mean age was 53.5 years with 54% males. When comparing 150mg QD with 75mg BID, 150mg QD resulted in ∼50% higher Cmax,ss, ∼50% lower Ctrough,ss and similar AUC0-24h,ss. No dose-limiting toxicity was observed. The most common treatment-related adverse events (TRAEs) (≥15%) included alanine aminotransferase (ALT) increase, aspartate aminotransferase (AST) increase, and anaemia. Grade ≥3 TRAE was reported in 5 patients, including anaemia, ALT increase, AST increase, bilirubin conjugated increase, blood bilirubin increase, gamma-glutamyltransferase increase, and pulmonary embolism. Hyperphosphatemia was reported in only 11% (3/28) of patients, and all were grade 1. One patient on 75mg BID experienced pulmonary embolism with a prior history, discerned as an unlikely related serious adverse event (SAE) by the investigators. Among the 5 patients with prior treatments and FGFR2 fusion/amplification or FGFR3 fusion, 2 achieved partial response (PR) and 2 achieved stable disease (SD). Objective response rate was 40%. All 4 patients are continuing treatment. Disease control rate was 80%. PR was observed in non-small cell lung cancer (FGFR2 fusion) and urothelial carcinoma (FGFR3 fusion). Conclusions This study demonstrated the anti-tumor activity of ABSK061 in patients with FGFR2/3 alterations and its favorable safety profile, which warrants further investigation.

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.